June 30, 2021
Walmart has announced the launch of the first-ever private brand analog insulin, which, the Bentonville, Arkansas-based retail behemoth says in a press release, will revolutionize the access to and affordability of diabetes care by offering customers a significant price savings without compromising quality.
The new private label ReliOn™ NovoLog® Insulin (insulin aspart) injection, manufactured by the Danish pharmaceutical firm Novo Nordisk, is available in Walmart pharmacies this week, and Sam’s Club pharmacies in mid-July across the United States.
ReliOn™ NovoLog® is a rapid-acting insulin analog used to control high blood sugar in adults and children with diabetes. Customers will need a prescription in order to purchase the products and should always consult with their doctor regarding their diabetes management.
“We know many people with diabetes struggle to manage the financial burden of this condition, and we are focused on helping by providing affordable solutions. We also know this is a condition that disproportionately impacts underserved populations. With ReliOn NovoLog insulin, we’re adding a high-quality medication for diabetes to the already affordable ReliOn line of products and continuing our commitment to improve access and lowering cost of care,” said Dr. Cheryl Pegus, executive vice president, Walmart Health & Wellness.
“Diabetes often comes with high medical costs, estimated around $9,601 per person per year. We welcome all affordable solutions that make diabetes management more accessible to millions of Americans living with diabetes. We encourage everyone to ask their health care provider questions to better understand what the right and affordable treatment is for their unique medical needs,” said Tracey D. Brown, CEO of the American Diabetes Association.
For additional information about Walmart’s affordable diabetes resources, visit Walmart.com/diabetes.
Research contact: @Walmart
